Firefly Neuroscience, Inc. - SIC # -

Ticker Exchange SIC # Website Latest Ticker
AIFF Nasdaq fireflyneuro.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Firefly Neuroscience, Inc.

Firefly Neuroscience to be Added to the Russell Microcap® Index - Jun 23rd, 2025 6:05 am
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients - Jun 20th, 2025 5:45 am
Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc. - May 5th, 2025 7:00 pm
Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc. - May 5th, 2025 5:45 am
Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01 - Mar 6th, 2025 5:30 am
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million - Feb 21st, 2025 6:00 am
Firefly Neuroscience Accepted into NVIDIA Connect Program - Feb 11th, 2025 5:45 am
Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics - Feb 7th, 2025 5:30 am
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care - Jan 24th, 2025 7:00 am
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform - Jan 14th, 2025 5:45 am
Firefly Neuroscience Closes on Financing of up to $12.4 Million - Dec 31st, 2024 7:00 am
Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman - Dec 4th, 2024 7:00 am
Firefly Neuroscience Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$0.18 loss in 3Q 2023) - Nov 16th, 2024 6:40 am
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - Nov 14th, 2024 3:30 pm
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event - Nov 6th, 2024 7:00 am
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 25th, 2024 2:10 pm
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data - Oct 21st, 2024 6:30 am
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology - Oct 16th, 2024 7:20 am
Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder - Oct 15th, 2024 7:00 am
Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis - Sep 20th, 2024 7:00 am